PhRMA, Sen. Grassley Dispute Over “Whistleblower” Law Wanes
This article was originally published in The Pink Sheet Daily
Executive Summary
Finance Chairman says the latest letter from the trade group regarding efforts to prevent fraudulent drug pricing and billing practices is more encouraging than their initial exchange. PhRMA says it will be in touch with committee staff to further discuss False Claims Act issues.
You may also be interested in...
Sen. Grassley Rejects PhRMA's Complaints About "Whistleblower" Law
In letters to PhRMA and the HHS Inspector General, finance chief rebukes trade association for being "out of tune" with its members on the False Claims Act. PhRMA asserts the FCA "stacks the deck" against drug makers in litigation and discourages internal complaints.
“Whistleblower” Suits Should Be Encouraged By Rx Manufacturers, Sen. Grassley Says
Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.
Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims
FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.